UK-based Ark Therapeutics' gene-based medicine EG011 for refractory angina, helped grow new blood vessels and restore heart function following a heart attack in a preclinical proof-of-principle study.
VEGF DDNDC, which had been identified by Ark as promising in a healthy heart model, showed superiority to the other VEGF forms producing a four-fold increase (p=0.0001) in the mean capillary area adjacent to the infarct within six days of injection. This effect was maintained out to 21 days with no signs of regression nor evidence of arteriole formation. A transient small increase (50% lower than VEGF A) in accumulation of pericardial fluid was evident in the treated area at day six following new capillary formation and this level had returned to control levels by day 21.
The left ventricle ejection fraction, which had dropped from nearly 70% before infarct to 46% after infarct, rose by over 16% (p=0.0002) with EG011, representing restoration of nearly 90% of the ventricular function. This compared favorably to a non-significant rise of around 2% in marker gene controls. EG011 appeared well tolerated with no differences in serious adverse events observed between active and control groups, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze